One to Watch: U.S. FDA Fast Tracks Azitra’s ATR-04 For Skin Rash from EGFR Inhibitors
The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for Azitra, Inc.’s topical ATR-04 to treat moderate to severe Epidermal Growth Factor Receptor inhibitor (EGFRi) associated dermal toxicity. ATR-04 is a live biotherapeutic product candidate containing an isolated, naturally derived Staphylococcus epidermidis strain that was engineered to be safer by deleting an antibiotic resistance […]